Skip to main content
SpringerLink
Log in

Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”

  • Letter
  • Published:
Advances in Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huang M, Fasching PA, Haiderali A, et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single agent pembrolizumab for high-risk early stage triple negative breast cancer in the United States. Adv Ther. 2023;40(3):1153–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl Med. 2020;382:810–21.

    Article  CAS  Google Scholar 

  3. Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) breast cancer version3.2023. 2023. https://www.nccn.org/. Accessed 13 Mar 2023.

  4. Chan ALF, Leung HWC, Lu C-L, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009;43(2):296–303.

    Article  PubMed  Google Scholar 

  5. Earl H, Hiller L, Vallier A-L, et al. Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess. 2020;24(40):1–190.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599–612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.

    Article  Google Scholar 

  8. Garrison LP, Babigumira J, Tournier C, et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in adjuvant treatment of HER2-positive breast cancer in the United States. Value Health. 2019;22(4):408–15.

    Article  PubMed  Google Scholar 

  9. Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol. 2021;39:1448–57.

    Article  CAS  PubMed  Google Scholar 

  10. Hayes DF. Defining clinical utility of tumor biomarker tests: a clinicians viewpoint. J Clin Oncol. 2021;39:238–48.

    Article  PubMed  Google Scholar 

  11. Cartun Z, Kunz WG, Heinzerling L, et al. Cost-effectiveness of response-adapted de-escalation of immunotherapy in advanced melanoma. JAMA Dermatol. 2022;158(12):1387–93.

    Article  PubMed  Google Scholar 

  12. Tu MM, Clemons M, Stober C, et al. Cost-effectiveness analysis of 12-versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer. Curr Oncol. 2021;28(3):1847–56.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Funding

No funding was received for the publication of this article.

Author Contributions

Steven Sorscher was the sole writer of this publication. Steven Sorscher meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, takes responsibility for the integrity of the work as a whole, and gave his approval for this version to be published.

Disclosures

Steven Sorscher is an employee of Biotheranostics, Inc./A Hologic Company.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human patients or animals performed by the author.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Author information

Authors and Affiliations

  1. Biotheranostics, Inc./A Hologic Company, 6333 Sequence Drive, San Diego, CA, 92121, USA

    Steven Sorscher

Authors
  1. Steven Sorscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Sorscher.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sorscher, S. Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”. Adv Ther 40, 4111–4113 (2023). https://doi.org/10.1007/s12325-023-02596-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-023-02596-w

Search

Navigation